Revista clinica espanola · 2026
Prognostic value of the Edmonton Obesity Staging System among people hospitalized with obesity.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ena J, Carretero Gomez J, Sanchez Lora F J, Bonilla Hernandez M V, Bustos Merlo A, Lobo-Antuña V, Miramontes Gonzalez J P, Gonzalez Gonzalez P, Nadal Gomez P, Hernández-Cerón C, Fernandez Rodriguez J M, Martinez Muriel B, Arcos Pereda P, Martinez A R, en nombre del Grupo de Trabajo de Diabetes, Obesidad y Nutrición de la Sociedad Española de Medicina Interna
Аннотация
BACKGROUND: Obesity is a heterogeneous clinical condition whose severity is not adequately reflected by body mass index (BMI). We used the Edmonton Obesity Staging System (EOSS), which integrates obesity-related comorbidities and functional impairment, to assess the prognosis of hospitalized patients with obesity.
METHODS: Prospective cohort study conducted in 26 Spanish hospitals. Hospitalised individuals with a BMI > 30 kg/m² were included. We evaluated sociodemographic and anthropometric variables, comorbidities, laboratory parameters, baseline treatment and treatment prescribed at discharge, EOSS stage, and outcomes at 90 days after discharge (readmissions and mortality).
RESULTS: Of 3,218 screened individuals, 496 (15.4%) were obese. The mean age was 75 years, and 50.1% were women. Most patients with obesity were classified into EOSS stages 2 (35.9%) and 3 (33.1%). Advanced stages were associated with higher comorbidity burden, worse laboratory profile (renal dysfunction, anaemia), and greater therapeutic complexity. As the EOSS stage increased, the trend analysis demonstrated a progressive increase in the risk of readmission (p = 0.026) and death (p = 0.023). In the discharge report, we recorded a significant relative increase in prescriptions of medications with cardiometabolic benefit and effect on body weight (relative increase of 33% for SGLT2 inhibitors and 11.8% for GLP-1/GLP1-GIP receptor agonists).
CONCLUSIONS: The EOSS classification system applied to hospitalized patients may identify subgroups of patients with worse prognosis helping physicians to initiate specific treatment to improve health outcomes.
METHODS: Prospective cohort study conducted in 26 Spanish hospitals. Hospitalised individuals with a BMI > 30 kg/m² were included. We evaluated sociodemographic and anthropometric variables, comorbidities, laboratory parameters, baseline treatment and treatment prescribed at discharge, EOSS stage, and outcomes at 90 days after discharge (readmissions and mortality).
RESULTS: Of 3,218 screened individuals, 496 (15.4%) were obese. The mean age was 75 years, and 50.1% were women. Most patients with obesity were classified into EOSS stages 2 (35.9%) and 3 (33.1%). Advanced stages were associated with higher comorbidity burden, worse laboratory profile (renal dysfunction, anaemia), and greater therapeutic complexity. As the EOSS stage increased, the trend analysis demonstrated a progressive increase in the risk of readmission (p = 0.026) and death (p = 0.023). In the discharge report, we recorded a significant relative increase in prescriptions of medications with cardiometabolic benefit and effect on body weight (relative increase of 33% for SGLT2 inhibitors and 11.8% for GLP-1/GLP1-GIP receptor agonists).
CONCLUSIONS: The EOSS classification system applied to hospitalized patients may identify subgroups of patients with worse prognosis helping physicians to initiate specific treatment to improve health outcomes.